Summary of Farvaris Conference Call Company and Industry Overview - **Company**: Farvaris - **Industry**: Pharmaceutical, specifically focusing on treatments for bradykinin mediated angioedema (HAE) Key Points and Arguments 1. **Introduction of Ducryptoban**: Farvaris is developing ducryptoban, an oral therapy aimed at treating bradykinin mediated angioedema, including types beyond hereditary angioedema (HAE) types one and two [2][4][16] 2. **Unmet Medical Needs**: There is a significant unmet need for effective treatments for patients with bradykinin mediated angioedema, particularly those with normal C1 inhibitor levels, which represent an additional 15-25% of patients [17][36] 3. **Clinical Trials**: Two pivotal Phase III studies are ongoing to evaluate the efficacy and safety of ducryptoban for both prophylactic and on-demand treatment of HAE attacks [17][33] 4. **Biomarker Development**: A novel biomarker assay has been developed to identify individuals with bradykinin mediated angioedema, which could enhance diagnosis and treatment management [24][31] 5. **Current Treatment Landscape**: The current treatment options for bradykinin mediated angioedema are limited, with many patients relying on off-label treatments that do not adequately address their needs [36][45] Additional Important Content 1. **Types of Angioedema**: The call discussed various types of bradykinin mediated angioedema, including hereditary angioedema due to C1 inhibitor deficiency and acquired forms, emphasizing the need for accurate diagnosis and tailored treatment approaches [8][10][12] 2. **Challenges in Diagnosis**: Diagnosing bradykinin mediated angioedema, especially in patients with normal C1 inhibitor levels, is challenging due to the lack of measurable biomarkers [11][23] 3. **Regulatory Support**: Farvaris has received orphan drug designation from both US and EU regulatory authorities for ducryptoban, highlighting the potential for this treatment to address significant unmet medical needs [45] 4. **Community Engagement**: Farvaris is collaborating with patient organizations and experts to better understand the needs of those living with bradykinin mediated angioedema [16][36] 5. **Future Directions**: The company aims to expand treatment options for patients with bradykinin mediated angioedema beyond HAE types one and two, with ongoing studies expected to provide critical data for regulatory filings [45][44] This summary encapsulates the key discussions and insights from the Farvaris conference call, focusing on the company's initiatives and the broader context of bradykinin mediated angioedema treatment.

Summary of Pharvaris (PHVS) Conference Call Company Overview - Pharvaris is focused on bradykinin-mediated angioedema, particularly hereditary angioedema (HAE) [3][4] - The company is pioneering science for patient choice in therapy options [3] - Pharvaris has two late-stage programs in Phase III for its molecule, Cryptevant, which serves both as prophylaxis and on-demand treatment [3][4] Market Insights - The global market for HAE is projected to grow to approximately $5.2 billion by 2036 [4] - There remains a significant unmet need in the HAE market, with no sustainable first-mover advantage for new entrants [4][5] - HAE is a genetic condition that significantly impacts the quality of life, with unpredictable attacks of swelling [5][6] Clinical Data and Pipeline - The prevalence of HAE is estimated to be between 1 in 10,000 to 1 in 80,000 individuals globally [7] - Patients typically experience around 12 to 24 attacks per year, influencing their treatment choices [8] - Cryptevant is a B2 receptor antagonist and the first and only small molecule orally available for this indication [9][10] - The company has two Phase III studies ongoing: RAPID E3 for on-demand treatment and Chapter III for prophylaxis, with top-line data expected in Q1 2026 and the second half of 2026, respectively [13][14] Efficacy and Safety - In Phase II studies, Cryptevant showed an 84.5% reduction in attacks at a 40 mg/day dosage compared to placebo [16][17] - The open-label extension study indicated a further 93% attack reduction compared to baseline [17] - The Phase III study for prophylaxis is designed to compare confirmed attacks against a placebo, with a focus on safety and efficacy [18][22] Future Plans and Regulatory Status - Pharvaris is planning a pivotal trial for acquired angioedema, with orphan drug status granted in Europe and the U.S. for both on-demand and prophylactic treatments [15] - The company aims to become a leader in the bradykinin-mediated angioedema space and is committed to engaging with the HAE community [23][24] Key Takeaways - Pharvaris is well-funded and has a strong R&D team with extensive experience in the therapeutic area [5] - The company is positioned to potentially become the standard of care in oral therapies for HAE, pending successful clinical trials and regulatory approvals [23][24]